Announcing PIPseq V, Fluent’s Newest Breakthrough in Single-Cell Analysis

Board Members

Mike Dybbs, Ph.D.

Investor, Board of Directors

Mike Dybbs is a partner at Samsara BioCapital, where he invests across all stages of the life-science sector—from seed stage to public equities. He currently serves on the boards of Samsara portfolio companies that include Enara Bio, IONpath, Levo Therapeutics, Nkarta Therapeutics, and Sutro (STRO). Prior to Samsara, Mike was a partner at New Leaf Venture Partners. Mike has served on the boards of Versartis (VSAR), Dimension Therapeutics (DMTX), Advanced Cell Diagnostics (acquired by Bio-Techne), and Principia. Before joining New Leaf, Mike was a principal at the Boston Consulting Group, serving as a core member of its healthcare practice.

Mike received a AB in biochemical sciences from Harvard University and a PhD in molecular biology from the University of California, Berkeley, which also awarded him a Howard Hughes Medical Institute fellowship.